Compound Library

Dual GIP/GLP-1 receptor agonist extensively studied in SURMOUNT and SURPASS trials for metabolic health and weight management research.

Triple agonist (GIP/GLP-1/Glucagon) under phase 2/3 investigation. Early trials show remarkable metabolic and weight-reduction signals.

Highly studied GLP-1 receptor agonist. STEP and SUSTAIN trial programs constitute some of the largest peptide clinical trial bodies in history.

GLP-1/Glucagon dual agonist under active phase 2/3 investigation for metabolic and NASH research.

Fragment of HGH (amino acids 176-191) studied specifically for lipolytic activity without the growth-promoting effects of full HGH.

Small molecule NNMT inhibitor studied for its potential in obesity and metabolic disease research contexts.

Nicotinamide adenine dinucleotide — central coenzyme in cellular energy metabolism. Extensively studied for roles in aging, DNA repair, and mitochondrial function.

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal gland research. Studied extensively in Soviet/Russian literature for telomere lengthening and longevity effects.

Mitochondrial-derived peptide encoded by the mitochondrial genome. Studied for roles in metabolic regulation, exercise performance, and longevity signaling.

Mitochondria-targeting peptide that selectively concentrates in the inner mitochondrial membrane. Studied for heart failure, kidney disease, and mitochondrial dysfunction.

Tripeptide (Glu-Asp-Arg) from pineal gland. Russian research program studied it for neuroprotective and longevity properties.

Master antioxidant tripeptide (GSH). Studied for detoxification support, oxidative stress reduction, immune function, and skin health applications.

Amino acid derivative critical for fatty acid transport into mitochondria. Studied for cardiovascular health, exercise performance, and metabolic support.

Body Protection Compound — pentadecapeptide derived from human gastric juice protein. Among the most researched peptides for tissue healing, tendon repair, and gut health.

Synthetic version of Thymosin Beta-4, an actin-sequestering protein studied for wound healing, cardiac protection, and inflammation modulation.

The Wolverine Stack — BPC-157 + TB-500 combined in one vial. BPC-157 coordinates local tissue repair (angiogenesis, collagen, growth factors) while TB-500 handles systemic cell migration and inflammation suppression. Named for Wolverine's regenerative healing ability.

KLOW is a four-peptide recovery and regeneration blend: BPC-157 + TB-500 + GHK-Cu + KPV. It extends the Wolverine Stack by adding GHK-Cu for deep regenerative gene signaling and KPV to suppress the chronic inflammation that blocks healing. The most comprehensive recovery stack currently discussed in peptide communities.

GLOW is a three-peptide recovery and skin rejuvenation blend: BPC-157 + TB-500 + GHK-Cu. The Wolverine Stack foundation with GHK-Cu added for collagen synthesis, anti-aging gene activation, and skin quality. Popular in wellness, skincare, and physical rejuvenation communities.

Copper peptide (Glycine-Histidine-Lysine) naturally present in plasma. Extensively researched for wound healing, collagen synthesis, anti-inflammatory, and skin rejuvenation properties.

C-terminal tripeptide of alpha-MSH (Lys-Pro-Val). Studied for anti-inflammatory properties, gut mucosal protection, and wound healing.

Engineered non-erythropoietic EPO analogue. Studied for neuropathic pain, nerve regeneration, and metabolic applications including beta-cell protection in diabetes research.

Long-acting GHRH analogue with Drug Affinity Complex (DAC) modification. Creates sustained GH pulse elevation through extended half-life via albumin binding.

Highly selective GH secretagogue and GHRP. Studied for its selective stimulation of GH without significant cortisol or prolactin elevation — considered the "cleanest" GHRP in research.

Combined CJC-1295/Ipamorelin studied for synergistic GH axis stimulation via dual-pathway mechanism — GHRH + GHRP synergy documented in literature.

First 29 amino acids of endogenous GHRH. FDA-approved (now withdrawn) GHRH analogue; most studied GH secretagogue with the longest clinical history.

Stabilized GHRH analogue (trans-3-hexenoic acid modification). FDA-approved for HIV-associated lipodystrophy. Extensively studied in multiple human RCTs.

Hexapeptide GH secretagogue. Early GHRP with potent GH-releasing activity; also stimulates ghrelin (orexigenic) pathways, driving appetite increase as a notable research finding.

Recombinant human growth hormone (somatropin). Most studied peptide hormone with decades of clinical trial data across multiple indications.

C-terminal fragment of HGH. Studied for isolated lipolytic activity, separating fat-burning effects from growth-promoting and anti-insulin effects of full HGH.

Long-acting IGF-1 analogue with arginine substitution and glutamate extension for reduced binding protein affinity. Higher bioavailability than native IGF-1.

Long-acting amylin analogue under investigation in combination with semaglutide (CagriSema). Amylin pathway complements GLP-1 mechanisms for potentially additive weight effects.

Melanocortin receptor agonist studied for sexual function (erectile and arousal pathways), skin pigmentation, and appetite suppression via CNS mechanisms.

Pro-apoptotic peptide that selectively destroys vasculature supplying white adipose tissue. Studied in primate models with dramatic fat reduction results.

Melanocortin receptor agonist (MC4R) studied for sexual dysfunction in both males and females. FDA-approved for HSDD in premenopausal women (Vyleesi).

Neuropeptide that activates GnRH release from hypothalamus. Studied in hypogonadotropic hypogonadism, sexual arousal, and reproductive axis regulation research.

Human chorionic gonadotropin — LH/CG receptor agonist. Extensively studied in hypogonadism, fertility, testosterone production, and testicular function preservation.

Neuropeptide hormone studied for social bonding, trust behavior, sexual arousal, anxiety reduction, and cardiovascular protective effects beyond reproductive function.

ACTH-derived heptapeptide developed in Russia. Studied for nootropic effects, BDNF upregulation, stroke recovery, and neurological protection. Approved in Russia and Ukraine as a drug.

Synthetic analogue of immunomodulatory peptide tuftsin. Studied for anxiolytic effects, cognitive enhancement, and immune modulation without sedation or dependence.

Delta Sleep-Inducing Peptide — neuropeptide studied for sleep architecture improvement, stress reduction, and HPA axis modulation.

Naturally occurring thymus-derived peptide. FDA-approved (Zadaxin) in 35+ countries. Most studied immune-modulating peptide with decades of clinical data in infectious disease and oncology.

Thymus-derived polypeptide complex from Khavinson Russian research program. Studied for immune restoration, longevity extension, and age-related immune decline reversal.

Only cathelicidin antimicrobial peptide in humans. Studied for broad-spectrum antimicrobial, immunomodulatory, wound healing, and potential anticancer properties.

Acetyl octapeptide analogue of SNAP-25. Studied for anti-wrinkle efficacy via neuromuscular junction modulation in skin research contexts — sometimes called "topical Botox alternative."

Vasoactive intestinal peptide — 28 amino acid neuropeptide studied for pulmonary hypertension, immune regulation, neuroprotection, and circadian rhythm research.

Sterile water for injection containing 0.9% benzyl alcohol as preservative. Standard reconstitution medium for lyophilized peptides in research settings. Preservative extends multi-use stability.

First-generation GLP-1 receptor agonist (Victoza/Saxenda). Once-daily injectable studied extensively for T2D glycemic control and obesity. Foundational molecule in the GLP-1 research class.

Oral non-peptide small molecule GLP-1 receptor agonist. First-in-class daily pill format studied as an alternative to injectable GLP-1 therapies. Phase 3 trials underway (Eli Lilly).

Twice-daily oral small molecule GLP-1 receptor agonist (Pfizer). Studied as pill-format GLP-1 alternative. Phase 3 program paused 2024 due to GI tolerability; research continues on modified release formulations.

Next-generation triple receptor agonist research class (GLP-1 + GIP + glucagon). Represents the frontier beyond tirzepatide dual agonism. Several candidates in research including LY3305677 and CT-996.

Direct NAD+ precursor studied for mitochondrial biogenesis, metabolic health, cardiovascular function, and longevity mechanisms. More bioavailable than NR for some tissues per recent comparative studies.

NAD+ precursor vitamin B3 analogue. First orally bioavailable NAD+ booster with human clinical trial data. Studied for cardiovascular health, neuroprotection, metabolic function, and healthy aging.

mTOR inhibitor — among the most studied longevity compounds. Extends lifespan in every model organism tested including mice. Human longevity trials ongoing (PEARL trial, Participatory Evaluation of Aging with Rapamycin). Immune-suppression drug repurposed for aging research.

Flavonoid polyphenol (found in strawberries, apples) studied as a senolytic — selectively clears senescent "zombie" cells. Mayo Clinic clinical trials ongoing for frailty and age-related conditions.

Naturally occurring polyamine found in aged cheese, wheat germ, and mushrooms. Studied as an autophagy inducer with potential for cardiovascular protection, neuroprotection, and lifespan extension. Declines naturally with age.

Mitochondrial electron transport chain cofactor. Studied for cardiovascular disease, statin-associated myopathy, heart failure, and mitochondrial dysfunction. Levels decline with age and statin use.

Full 43-amino-acid thymosin beta-4 molecule (parent compound; tb500 is the active fragment). Studied for cardiac repair, wound healing, hair follicle stimulation, and anti-inflammatory signaling. Different pharmacology from tb500 fragment.

Tight junction regulator studied for celiac disease, leaky gut, and intestinal permeability research. Competitive inhibitor of zonulin — the protein that opens intestinal tight junctions. Phase 3 trials conducted for celiac.

Semi-synthetic polysaccharide studied for joint cartilage repair, interstitial cystitis, and osteoarthritis. Approved drug (Elmiron) for IC. Joint injection studies show cartilage regeneration signals.

Lipid-linked pentapeptide that signals fibroblasts to produce collagen, elastin, and hyaluronic acid. Widely studied in cosmetic dermatology as a collagen-stimulating topical. Matrikine peptide class.

Neuroprotective peptide fragment derived from nerve growth factor signaling pathways. Studied for peripheral nerve regeneration, spinal cord injury recovery models, and neurotrophic repair applications.

Second-generation GH-releasing hexapeptide. More potent GH pulse amplitude than GHRP-6 with less ghrelin-mediated appetite stimulation. Studied for GH deficiency, body composition, and anti-aging hormone optimization.

Potent synthetic hexapeptide GH secretagogue — among the most potent GHS-R1a agonists. Studied for cardiac repair beyond GH axis effects via direct CD36 receptor activity. Orphan drug potential for growth hormone deficiency.

Orally active non-peptide GH secretagogue. Only oral GHS-R1a agonist compound in widespread research. Sustained IGF-1 elevation with once-daily oral dosing makes it uniquely convenient in the GH secretagogue class.

Stabilized 29-amino acid GHRH analogue without the DAC modification of CJC-1295. Shorter acting than CJC-1295-DAC — produces physiological-style GH pulses. Often combined with GHRP-2 or ipamorelin for synergistic GH release.

GHRH analogue without the Drug Affinity Complex (DAC) modification. Functionally identical to Modified GRF(1-29). Short-acting GHRH analogue favored by researchers who prefer pulsatile GH release over the sustained "GH bleed" of the DAC version.

Soluble activin receptor type IIB (ActRIIB) fusion protein — potent myostatin pathway inhibitor. Studied for Duchenne muscular dystrophy and muscle wasting. Dramatically increases lean mass in human trials before safety pause.

Endogenous myostatin and activin antagonist. Studied for muscle hypertrophy, fertility, and metabolic effects. Significantly increases lean body mass in animal models. Limited human pharmacokinetic data.

Approved aphthous ulcer treatment (Aphthasol) being repurposed as metabolic compound. Inhibits TBK1 and IKKε kinases, reversing metabolic effects of obesity-induced inflammation. Studied for weight loss, insulin sensitivity, and NASH.

Steroidal SARM with unique dual mechanism: androgen receptor partial agonist AND myostatin inhibitor via follistatin induction. Studied for exceptional anabolic potential with potentially lower androgenic side effects than testosterone. Research compound only.

Full-length 54 amino acid kisspeptin — the master regulator of the HPG axis. Studied for hypogonadotropic hypogonadism, IVF triggering, and pubertal development. Kisspeptin-10 is the active C-terminal fragment.

Linear melanocortin MC1R agonist (parent to MT-II). FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP). Studied for photoprotection, tanning, and skin disorder research. Lacks the sexual side effects of MT-II.

Cyclic melanocortin peptide (same active compound as PT-141 but characterized in injectable research context). FDA-approved as Vyleesi for HSDD in premenopausal women. Studies in male sexual dysfunction ongoing.

Hepatocyte growth factor receptor (HGF/c-Met) agonist peptide. Described in preclinical studies as millions of times more potent than BDNF for synaptogenesis. Studied for Alzheimer disease, cognitive enhancement, and neurological repair.

Proline-containing dipeptide nootropic studied for cognitive enhancement, neuroprotection, and anxiety reduction. Developed in Russia. Rapidly crosses BBB; active at nanogram doses. Different mechanism from racetam class.

Neuropeptide mixture derived from pig brain tissue. Contains BDNF, NGF, GDNF, CNTF, and other neurotrophic peptide fragments. Studied for Alzheimer's disease, traumatic brain injury, stroke recovery, and ADHD. Widely used in Russia and China.

PSD-95 inhibitor peptide studied for acute ischemic stroke neuroprotection. Designed to prevent excitotoxic neuronal death post-stroke. Phase 3 ESCAPE-NA1 trial completed with notable subgroup findings.

Polypeptide complex extracted from porcine/bovine cerebral cortex tissue. Contains multiple neurotrophic peptides. Studied for childhood cognitive development, stroke rehabilitation, and neuroprotection in Russia and Eastern Europe.

Zinc-dependent thymic nonapeptide — only thymic hormone requiring a cofactor for activity. Studied for immune restoration, anti-inflammatory effects, and has demonstrated analgesic properties in pain models. Declines with thymic involution.

PEGylated form of thymalin with extended half-life designed for less frequent dosing. Studied for prolonged immune restoration and longevity applications. Pegylation technology applied to thymic peptide class.

Recombinant interleukin-2 at ultra-low doses studied for regulatory T-cell (Treg) expansion in autoimmune disease and immune aging. Distinct from high-dose IL-2 cancer immunotherapy — entirely different mechanism and safety profile at ultra-low doses.

Thymosin alpha-1 (Zadaxin) in extended/chronic administration research protocols — distinct from standard acute infection courses. Studied for long-term immunosenescence reversal, chronic viral infection suppression, and longevity applications in aging immune systems.

Lipid-conjugated tripeptide that activates TGF-β signaling to stimulate collagen synthesis. Studied alongside Matrixyl (palmitoyl pentapeptide-4) for complementary anti-aging dermatology research. Part of the Matrixyl 3000 combination.

SNAP-25 N-terminal sequence acetylated hexapeptide. Studied as topical neuromuscular junction modulator for expression-line reduction. "Topical Botox" research category — same SNARE complex target as SNAP-8.

Pentapeptide enkephalin analogue that acts on opioid receptors in nerve terminals to reduce acetylcholine release at neuromuscular junctions. Studied in combination with argireline for synergistic expression-line reduction.

Extended research compound entry for GHK-Cu copper peptide complex including systemic administration studies beyond topical use. Studied for lung fibrosis (anti-fibrotic), wound contraction, nerve regeneration, and anti-tumor effects.